Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
Interventions: Acalabrutinib, Rituximab; Drug
Lead sponsor: Shayna Sarosiek, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Impaired Glucose Tolerance
Interventions: Resveratrol, resveratrol /HMB, Placebo treatment; Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more

Conditions: Carpal Tunnel Syndrome
Interventions: Methylprednisolone Injection [Solu-Medrol], wrist splint; Drug · Device
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Breast Cancer
Interventions: Temsirolimus, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 4
States / cities: Goodyear, Arizona • Los Angeles, California • New York, New York

Conditions: Tobacco Use, Tobacco Smoking, Tobacco Use Cessation
Interventions: opt out enrollment, tailored counseling, varenicline started prior to target quit date, opt in enrollment, non-tailored counseling, varenicline started prior to target quit date; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Healthy Volunteers, Elevated CRP
Interventions: MRT-8102, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Durvalumab, Olaparib; Biological · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hunger
Interventions: psyllium fiber 6.8g, placebo; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: HSV Infection
Interventions: Pritelivir, ESO and pritelivir; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Colorectal Cancer Prevention
Interventions: Regular Diet, Navy Beans (Canned); Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: TV-46000, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 67
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Comprehensive Geriatric Assessment, Health Education, Medical Device Usage and Evaluation, Supportive Care; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes, Obesity
Interventions: Meal Replacement, Standard Care; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Graft Versus Host Disease, JNS Kinase, Topical Administration
Interventions: Ruxolitinib 1.5% cream, vehicle cream; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stroke
Interventions: TPAD (Tethered Pelvic Assist Device); Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Mild Traumatic Brain Injury
Interventions: [18F]PI-2620; Drug
Lead sponsor: Life Molecular Imaging SA.; Industry
Eligibility: 25 Years to 54 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 499
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more

Conditions: Non Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: LIFE-L Mediterranean Diet, LIFE-L Home-Based Exercise Program, Supportive Materials; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Knee Osteoarthritis
Interventions: SM04690, Placebo, Sham; Drug · Other
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 74
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more

Conditions: Myeloma
Interventions: KLH Vaccine, KLH-id Vaccine, GM-CSF, Apheresis, Donor Lymphocyte Infusion (DLI); Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Tobacco Cessation at FDNY

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial

A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia

Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment

A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population

Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

Reducing Asymmetry During Gait Using the TPAD (Tethered Pelvic Assist Device) for Stroke Patients

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant